PL1593390T3 - Terapeutyczne koncentraty białek osocza zawierające czynnik von Willebranda w postaci multimerów o dużej masie cząsteczkowej - Google Patents

Terapeutyczne koncentraty białek osocza zawierające czynnik von Willebranda w postaci multimerów o dużej masie cząsteczkowej

Info

Publication number
PL1593390T3
PL1593390T3 PL05008693T PL05008693T PL1593390T3 PL 1593390 T3 PL1593390 T3 PL 1593390T3 PL 05008693 T PL05008693 T PL 05008693T PL 05008693 T PL05008693 T PL 05008693T PL 1593390 T3 PL1593390 T3 PL 1593390T3
Authority
PL
Poland
Prior art keywords
molecular weight
high molecular
von willebrand
concentrates containing
weight multimers
Prior art date
Application number
PL05008693T
Other languages
English (en)
Inventor
Hans-Peter Hauser
Olaf Walter
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL1593390T3 publication Critical patent/PL1593390T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05008693T 2004-05-05 2005-04-21 Terapeutyczne koncentraty białek osocza zawierające czynnik von Willebranda w postaci multimerów o dużej masie cząsteczkowej PL1593390T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04010721A EP1593388A1 (en) 2004-05-05 2004-05-05 Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
EP05008693A EP1593390B1 (en) 2004-05-05 2005-04-21 Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers

Publications (1)

Publication Number Publication Date
PL1593390T3 true PL1593390T3 (pl) 2011-04-29

Family

ID=34924882

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05008693T PL1593390T3 (pl) 2004-05-05 2005-04-21 Terapeutyczne koncentraty białek osocza zawierające czynnik von Willebranda w postaci multimerów o dużej masie cząsteczkowej

Country Status (11)

Country Link
US (1) US7335634B2 (pl)
EP (2) EP1593388A1 (pl)
JP (2) JP2005320330A (pl)
KR (1) KR101241061B1 (pl)
AT (1) ATE489104T1 (pl)
AU (1) AU2005201923B2 (pl)
CA (1) CA2506218C (pl)
DE (1) DE602005024886D1 (pl)
DK (1) DK1593390T3 (pl)
ES (1) ES2356158T3 (pl)
PL (1) PL1593390T3 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022202A1 (en) * 2008-08-20 2010-02-25 Bio/Data Corporation Kinetic biologic activity assays and kinetic von willebrand assay
ES2761692T5 (es) 2010-07-08 2023-07-05 Takeda Pharmaceuticals Co Método de producción de vWF recombinante de alto peso molecular en cultivo celular
HUE039317T2 (hu) 2011-06-10 2018-12-28 Baxalta GmbH Koagulációs betegség kezelése rekombináns VWF adagolásával
DK3265489T3 (da) * 2015-03-06 2019-07-15 CSL Behring Lengnau AG Forbindelser til forbedring af halveringstiden af von willebrand faktor
AU2018298233A1 (en) 2017-07-07 2020-01-30 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
WO2019010496A1 (en) * 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6288613B1 (en) * 2000-06-15 2001-09-11 Nortel Networks Limited Bias circuits for depletion mode field effect transistors
DE10246125A1 (de) * 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren

Also Published As

Publication number Publication date
AU2005201923B2 (en) 2010-03-11
DK1593390T3 (da) 2011-02-28
EP1593390A1 (en) 2005-11-09
JP2005320330A (ja) 2005-11-17
EP1593390B1 (en) 2010-11-24
CA2506218C (en) 2013-06-25
CA2506218A1 (en) 2005-11-05
AU2005201923A1 (en) 2005-11-24
EP1593388A1 (en) 2005-11-09
ES2356158T3 (es) 2011-04-05
KR101241061B1 (ko) 2013-03-11
KR20060047741A (ko) 2006-05-18
US7335634B2 (en) 2008-02-26
US20050282735A1 (en) 2005-12-22
DE602005024886D1 (de) 2011-01-05
ATE489104T1 (de) 2010-12-15
JP2011173923A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
PL1593390T3 (pl) Terapeutyczne koncentraty białek osocza zawierające czynnik von Willebranda w postaci multimerów o dużej masie cząsteczkowej
WO2006071801A3 (en) Polymer-von willebrand factor-conjugates
Abul-Azm et al. Effect of topical tranexamic acid in open heart surgery
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
JP2009137992A5 (pl)
ES2910948T3 (es) Almacenamiento anaeróbico de sangre y procedimiento de inactivación de patógenos
HK1112429A1 (en) Compositions and their use for enhancing vascular access
EP1381345A4 (en) TREATMENT ADMINISTRATION AGAINST AQUACULTURE AND AGRICULTURE DISEASE USING MICROBES CONTAINING BIO-ACTIVE PROTEINS
PA8453501A1 (es) Derivados dipeptidicos
DE60323323D1 (de) Sterilisation von Kits mit medizinischen Klebstoffzusammensetzungen
ATE555815T1 (de) Verfahren zur bestrahlung von thrombozytenkonzentraten in flexiblen behältnissen mit ultraviolettem licht
IL172844A0 (en) Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment
HK1075406A1 (en) Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin
PL371200A1 (pl) Zestaw hemostatyczny, sposób wytwarzania środka hemostatycznego i sposób pobudzania hemostazy
AU2003295325A8 (en) Heart bypass system incorporating minimized extracorporeal blood circulation system and related method of use
Burnouf et al. Blood‐derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue
AU2003274686A8 (en) Inhibitors of the gpib -vwf interaction, their preparation and use
JP2008511674A5 (pl)
DE50303099D1 (de) Patientenlagerungstisch
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ITMI20021553A1 (it) Emoconcentratore in circuito ematico extracorporeo
AU2461001A (en) Photodynamic inactivation of pathogens in blood by phenothiazines and oxygen
GR1003885B (el) Μη-πεπτιδικοι μιμητες της δραστικης αλληλουχιας s42fllr46 του υποδοχεα της θρομβινης για την θεραπεια της θρομβωσης και του καρκινου
Deconinck et al. Inhibition of ADAMTS13 prevents the loss of high molecular weight von Willebrand factor multimers in an in vitro left ventricular assist device
Nair et al. Blood-derived products